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Abstract 
Pseudomembranous colitis (PMC) may develop with long-term antibiotic administration, 
but is rarely reported to be caused by antitubercular agents. We present a case of PMC 
that occurred 120 days after starting rifampicin. A 74-year-old man was diagnosed with 
pulmonary tuberculosis and started on a standard HERZ regimen (isoniazid, ethambutol, 
rifampicin, pyrazinamide). After 4 months of HERZ, he presented with frequent bloody, 
mucoid, jelly-like diarrhea and lower abdominal pain. Sigmoidoscopy revealed multiple 
whitish plaques with edematous mucosa that were compatible with PMC. Biopsies from 
these lesions showed ulcer-related necrotic and granulation tissue. We stopped 
antitubercular treatment and started the patient on oral metronidazole. His symptoms 
completely resolved within 2 weeks. Antitubercular treatment was restarted by replacing 
rifampicin with levofloxacin. The patient did not present with diarrhea or bloody stool 
throughout the rest of treatment. 
Introduction 
Pseudomembranous colitis (PMC) is characterized by the presence of yellow or white 
plaques on the mucosal surface that are composed of inflammatory exudates [1]. PMC is 
associated with the administration of antibiotics that alter the normal gastrointestinal 
flora and allow overgrowth of Clostridium difficile. The frequency of this complication 
varies among antibacterial agents [2], and it is rarely associated with antitubercular 
agents.   
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Isoniazid and ethambutol have few effects on intestinal flora, but rifampicin has 
antibiotic effects over a wide range of bacteria [3] and therefore may cause PMC when 
PMC develops in association with antitubercular treatment. Here, we document a case of 
PMC that developed 4 months after initiation of rifampicin administration. 
Case Report 
A 74-year-old man was diagnosed with pulmonary tuberculosis via an abnormal chest X-ray and 
acid fast bacilli sputum smear (fig. 1). Antitubercular agents, including isoniazid (400 mg/day), 
rifampicin (600 mg/day), pyrazinamide (1,500 mg/day), and ethambutol (800 mg/day) were 
administered. Four months after initiation of antitubercular treatment, the patient complained of 
intermittent loose stool, tenesmus, and lower abdominal discomfort. Fifteen days later, his diarrhea 
became bloody and mucoid with a jelly-like appearance, and he suffered from aggravating lower 
abdominal discomfort. By the time the patient presented to our hospital, he was experiencing bloody 
diarrhea 5 to 6 times per day.  
On physical examination, the patient was febrile, and his vital signs were within normal limits. His 
bowel movements were very frequent and his abdomen was soft and flat. Tenderness was noticed in the 
left lower quadrant of the abdomen without rebound tenderness. The patient’s white blood cell count 
was 5,300/mm
3, but serum C-reactive protein and erythrocyte segmentation rate were markedly 
elevated at 4.41 mg/dl and 57 mm/h, respectively. Sigmoidoscopy revealed multiple yellowish plaque 
lesions from the rectum to the sigmoid colon (fig. 2a), and mucosal biopsy from the sigmoid colon 
showed small collections of neutrophils between crypts at the summit of the mucosa with tufts of 
damaged surface epithelium (fig. 3).  
The patient was diagnosed with PMC. We discontinued antitubercular agents and started oral 
metronidazole 250 mg twice per day with intravenous fluid and electrolytes. The patient’s symptoms 
ameliorated slowly over 2 weeks of metronidazole treatment, during which he completely recovered 
from diarrhea, tenesmus, and abdominal pain. We restarted antitubercular agents, replacing rifampicin 
with levofloxacin. The patient experienced no recurrence of diarrhea by the end of antitubercular 
treatment, and his general condition recovered. Follow-up sigmoidoscopy did not show any evidence of 
PMC (fig. 2b). 
Discussion 
Rare cases of rifampicin-associated PMC have been reported since the 1980s [3–7]. 
Among antitubercular agents, rifampicin has been implicated as a cause of PMC due to its 
relatively wide range of antibiotic effects, whereas isoniazid and ethambutol have few 
effects on the intestinal flora [3]. Most C. difficile strains are susceptible to rifampicin [8], 
but resistance can develop after prolonged use [9]. The best method to ascertain whether 
PMC is induced by rifampicin consists of retrial with a single regimen of rifampicin and 
observation of recurrence. However, we did not retry rifampicin because our patient was 
elderly and in poor general condition due to his prolonged illness. We achieved a 
successful result after replacing rifampicin with levofloxacin, which suggests that 
rifampicin was responsible for PMC in our patient, although this was not confirmed 
bacteriologically. 
In most patients with PMC, diarrhea occurs after 5 to 10 days of antibiotic 
administration [10]. However, as shown in table 1, rifampicin-associated PMC may occur 
7 to 240 days (mean 56.6 days) after the initiation of rifampicin administration. Our 
patient developed diarrhea 120 days after initiating rifampicin. A long latency period is 
not unusual in rifampicin-associated PMC. Symptoms usually improve under treatment  
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with vancomycin or metronidazole, and one patient was reported to recover after 
treatment with lactic acid bacilli only [3].  
Oral therapy with metronidazole 250 mg, 4 times per day for 10 days, is the 
recommended first-line therapy for PMC. A regimen of vancomycin, 125 to 
500 mg, 4 times per day for 10 days, should be limited to patients who cannot 
tolerate or have not responded to metronidazole, or administered in the context of 
metronidazole-resistent organisms such as enterococci [11]. The yeast Saccharomyces 
boulardii has been shown in controlled trials to reduce recurrences when given as an 
adjunct to antibiotic therapy [12]. 
Clinicians who are managing aged, tuberculosis-infected patients must keep in mind 
the possibility of antitubercular agent-associated PMC and should remember that 
rifampicin-associated PMC has a wide range of latency periods, 1 week to 8 months after 
the initiation of rifampicin administration. 
 
 
  
Case Rep Gastroenterol 2011;5:45–51 
DOI: 10.1159/000323753 
Published online: 
January 14, 2011 
© 2011 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
48
Table 1. Characteristics of reported patients with rifampicin-associated pseudomembranous colitis 
Case  Age  
(years), 
sex 
Tuberculosis  Liver 
disorder 
Other 
condition 
Other 
anti-Tbc 
drugs 
Latency 
to Sx 
develop-
ment 
Manifestation  Endoscopic findings  Patho- 
logic 
diagno-
sis 
C. 
difficile, 
toxin 
Treatment 
01  59, F  miliary  liver 
damage 
by RFP 
Candida 
infection 
INH, M  020  F, D, J  firm rectal mucosa  yes  ND  VCM, 
cholestyr-
amine 
02  57, M  kidney      INH, EB  007  P, D, F, H, T  edema, patchy 
purpura/pseudo-
membranes 
  (–, ND)  none 
03  60, M  meninx  not 
mentioned 
  INH, EB  028  D  typical of PMC  yes  (+, –)  VCM 
04  56, F  lung  alcoholic 
LC 
  INH, M, 
SM 
032  F, D, P  hyperemic mucosa, 
pseudomembranes 
yes  (–, ND)  VCM 
05  65, F  pleura, skin      INH  240  D, P, T  pseudomembranes  yes  ND  VCM 
06  18, F  lung  not 
mentioned 
  INH, EB, 
SM 
038  D, P  pseudomembranes  yes  (+, +)  cholestyr-
amine 
07  64, F  miliary  miliary 
tubercu-
losis 
  INH, EB  026  F, P, D  not mentioned  yes  (+, ND) VCM 
08  ?, M        EB, SM  070      NA  (–, –)  NA 
09  18, M  lung      INF, PZ  017  D, P, V, F, Pe  mild inflammation  yes  (+, +)  surgery 
10  52, F  lung      INF, PZ  021  F, P, D  friable mucosa, 
ulceration 
yes  (–, +)  MNZ 
11  60, M  lung      INH  120  D  consistent with 
PMC 
yes  (+, ND) MNZ 
12  86, F  lung    HT,  
IHD 
INH, EB, 
PZ 
112  P, D  typical of PMC  yes  (ND, –)  VCM 
13  58, F  lung, pleura, 
AIH (LC) 
    INH, EB  060  D, H, P, F  aphthoid lesions/ 
pseudomembranes 
yes  (–, ND)  lactic acid 
bacteria 
14  77, M  pleura      INH, EB, 
PZ 
010  D, T  consistent with 
PMC 
yes  (–, +)  VCM 
15  50, F  lung    DM  INH, EB, 
PZ 
056  D, P, T  consistent with 
PMC 
yes  (–, –)  MNZ 
16  90, M  lung      INH, EB, 
PZ 
045  D, H, P, T  consistent with 
PMC 
yes  (–, –)  MNZ 
17  70, M  lung      INH, EB, 
PZ 
020  D, P  consistent with 
PMC 
yes  ND   
18  66, F  intestine    DM, 
HT 
INH, EB, 
PZ 
060  P  patch, 
pseudomembranes 
yes  (+, –)  MNZ 
19  32, F  lung      INH, EB, 
PZ 
030  P, D  edema, hyperemic 
mucosa 
yes  (+, –)  MNZ 
Our 
patient 
74, M  lung    DM, 
HT 
INH, EB, 
PZ 
120  D, H  friable mucosa, 
pseudomembranes 
yes  ND  MNZ 
AIH = Autoimmune hepatitis; C. difficile = Clostridium difficile; D = diarrhea; DM = diabetes mellitus; EB = ethambutol; 
F = fever; H = hematochezia; HT = hypertension; IHD = ischemic heart disease; INF = interferon; INH = isoniazid; J = jaundice; 
LC = liver cirrhosis; M = myambutol; MNZ = metronidazole; NA = not available; ND = not determined; P = pain; Pe = perforation; 
PMC = pseudomembranous colitis; PZ = pyrazinamide; RFP = rifampicin; SM = streptomycin; Sx = symptom; T = tenesmus; 
Tbc = tuberculosis; V = vomiting; VCM = vancomycin. 
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Fig. 1. A chest radiograph taken at admission demonstrates whitish patch consolidations on the right 
upper lung field suggesting pulmonary tuberculosis. The right middle and lower lung fields are also 
involved with patch consolidations but show much less whitish patches than those of the right upper 
lung field. Contrasting to the right lung field, the left lung field does not show abnormal findings. 
There are no vascular abnormalities and no bony thorax abnormalities. 
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Fig. 2. a Sigmoidoscopy demonstrates multiple whitish to yellowish plaques, 5 to 8 mm in size. Many 
whitish to yellowish plaques are aggregated with much exudate and some fresh blood or scattered on the 
whole sigmoid colon. Multiple hyperemic erosive lesions are also scattered on the whole sigmoid colon 
with edematous mucosa. b Sigmoidoscopy, after 2 weeks of metronidazole treatment, shows that the 
multiple whitish to yellowish plaques and accompanied small erosions, responsible for bleeding, have 
disappeared completely. Pinkish mucosa with fine normal vascular patterns, which is not observed in a 
due to edema, is observed. 
 
 
 
Fig. 3. Pathologic findings reveal innumerous neutrophils aggregated and infiltrated between 
superficial crypts at the surface of the colonic mucosa. Infiltration of aggregated neutrophils induces 
distension and damage of superficial crypts. Fragments of damaged surface epithelium are also 
observed with much mucus material and numerous red blood cells. Hematoxylin and eosin staining, 
×200. 
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